tiprankstipranks
Esperion upgraded to Neutral from Underperform at Credit Suisse
The Fly

Esperion upgraded to Neutral from Underperform at Credit Suisse

Credit Suisse upgraded Esperion Therapeutics to Neutral from Underperform with a price target of $7, up from $6.50. The analyst sees more limited downside risk following release of the full CLEAR Outcomes trial dataset. The CLEAR data represented the "last hard catalyst" for Esperion until the anticipated bempedoic acid label change and related Daiichi milestone in the first half of 2024, the analyst tells investors in a research note.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ESPR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles